Fungal infections remain a critical unmet medical need with millions of infections occurring annually. With only three classes of antifungal drugs available, drug resistance and modest activity toward some fungi represent threats to human health. To address this, optimization of the antifungal properties of approved drugs with appropriate pharmacokinetic properties represents an attractive strategy. Here, we have shown that the antifungal activity of phenothiazine-based